期刊
NATURE REVIEWS DRUG DISCOVERY
卷 11, 期 3, 页码 215-233出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/nrd3626
关键词
-
资金
- Ligue contre le Cancer (the French National League against Cancer)
- AXA Chair for Longevity Research
- Canceropole Ile-de-France
- Institut National du Cancer (the French National Cancer Institute)
- Bettencourt-Schueller Foundation
- Fondation de France
- Fondation pour la Recherche Medicale (the Foundation for Medical Research)
- Agence National de la Recherche (the National Agency for Research)
- European Commission (APO-SYS, ArtForce, ChemoRes. Death-Train)
- LabEx Immuno-Oncology
It has recently become clear that the tumour microenvironment, and in particular the immune system, has a crucial role in modulating tumour progression and response to therapy. Indicators of an ongoing immune response, such as the composition of the intratumoural immune infiltrate, as well as polymorphisms in genes encoding immune modulators, have been correlated with therapeutic outcome. Moreover, several anticancer agents - including classical chemotherapeutics and targeted compounds - stimulate tumour-specific immune responses either by inducing the immunogenic death of tumour cells or by engaging immune effector mechanisms. Here, we discuss the molecular and cellular circuitries whereby cytotoxic agents can activate the immune system against cancer, and their therapeutic implications.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据